STAAR Surgical Company

DB:SR3 Stock Report

Market Cap: €1.3b

STAAR Surgical Valuation

Is SR3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SR3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SR3 (€26.69) is trading below our estimate of fair value (€61.16)

Significantly Below Fair Value: SR3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SR3?

Key metric: As SR3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SR3. This is calculated by dividing SR3's market cap by their current earnings.
What is SR3's PE Ratio?
PE Ratio63.7x
EarningsUS$21.78m
Market CapUS$1.39b

Price to Earnings Ratio vs Peers

How does SR3's PE Ratio compare to its peers?

The above table shows the PE ratio for SR3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.6x
PHH2 Paul Hartmann
12.5xn/a€745.9m
EUZ Eckert & Ziegler
26.7x5.2%€943.0m
DRW3 Drägerwerk KGaA
7.2x2.0%€792.5m
NXU Nexus
44.1x17.1%€1.2b
SR3 STAAR Surgical
63.7x33.7%€1.4b

Price-To-Earnings vs Peers: SR3 is expensive based on its Price-To-Earnings Ratio (63.7x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does SR3's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SR3 63.7xIndustry Avg. 29.6xNo. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SR3 is expensive based on its Price-To-Earnings Ratio (63.7x) compared to the European Medical Equipment industry average (29.8x).

Price to Earnings Ratio vs Fair Ratio

What is SR3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SR3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio63.7x
Fair PE Ratio36.7x

Price-To-Earnings vs Fair Ratio: SR3 is expensive based on its Price-To-Earnings Ratio (63.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SR3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€26.69
€40.82
+53.0%
23.1%€56.99€25.65n/a11
Nov ’25€26.16
€41.04
+56.9%
21.6%€55.37€24.92n/a10
Oct ’25€33.14
€44.72
+35.0%
15.9%€54.16€33.40n/a10
Sep ’25€28.80
€45.12
+56.7%
16.0%€53.61€33.06n/a11
Aug ’25€37.94
€47.01
+23.9%
14.9%€55.06€33.95n/a11
Jul ’25€44.04
€48.11
+9.2%
13.1%€55.85€37.24n/a10
Jun ’25€37.24
€48.11
+29.2%
13.1%€55.18€36.79n/a9
May ’25€44.04
€45.82
+4.0%
19.5%€55.92€30.76n/a9
Apr ’25€34.60
€40.02
+15.7%
17.6%€48.51€29.29n/a9
Mar ’25€28.80
€37.69
+30.9%
21.3%€48.87€27.66n/a8
Feb ’25€25.83
€38.78
+50.1%
20.8%€48.65€27.54n/a8
Jan ’25€28.89
€41.00
+41.9%
19.5%€50.90€29.99n/a9
Dec ’24€28.65
€44.59
+55.6%
16.6%€52.29€32.68n/a8
Nov ’24€39.22
€48.94
+24.8%
16.6%€60.56€37.85€26.167
Oct ’24€37.53
€49.94
+33.1%
17.1%€60.96€37.51€33.148
Sep ’24€39.71
€52.00
+31.0%
12.4%€60.69€41.38€28.809
Aug ’24€49.51
€63.84
+28.9%
11.6%€74.71€48.92€37.949
Jul ’24€47.45
€69.33
+46.1%
12.7%€77.54€50.17€44.049
Jun ’24€53.56
€73.15
+36.6%
13.0%€88.22€55.72€37.249
May ’24€61.96
€70.96
+14.5%
11.9%€82.34€54.89€44.049
Apr ’24€57.08
€74.98
+31.4%
10.8%€84.89€56.59€34.608
Mar ’24€52.40
€74.98
+43.1%
10.8%€84.89€56.59€28.808
Feb ’24€64.46
€74.06
+14.9%
14.9%€96.80€55.31€25.839
Jan ’24€44.48
€75.62
+70.0%
14.9%€98.97€56.56€28.899
Dec ’23€54.32
€82.06
+51.1%
9.7%€100.78€74.86€28.658
Nov ’23€71.34
€103.45
+45.0%
14.3%€128.51€87.39€39.228

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%